^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | GDC 0879 (BRAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
Excerpt:
The potency of GDC-0879 for a panel of melanoma, colorectal, and non–small-cell lung cancer cell lines....Tumor cells with oncogenic mutations in either KRAS or NRAS showed limited dependence on BRAF activity and were frequently resistant to GDC-0879 treatment in vitro (EC50 > 7.5 μmol/L for 28 of 32 cell lines.
DOI:
10.1158/0008-5472.CAN-08-3563
